The potential change outlined in a statement would require all new vaccines to undergo “placebo” testing, sparking concerns ...

The US Department of Health and Human Services said it will require that all new vaccines be tested in placebo-controlled ...

Pfizer Inc. and BioNTech SE failed to knock out any of Alnylam Pharmaceuticals Inc.’s patents in a case over the partners’ ...

As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly ...

“Flash forward to more modern times – when the first ... transformed and accelerated the science of new vaccine development, ...

Novavax (NVAX) announced preliminary results from the SHIELD-Utah study that showed Novavax’s COVID-19 Vaccine, Adjuvanted 2024-2025 Formula ...

Research teams across Canada are now building on homegrown innovation to expand the potential of RNA vaccines beyond ...

In GSK’s suit against Pfizer, the British pharma was seeking monetary damages or royalties and potentially a permanent injunction on the commercialization of Pfizer’s RSV vaccine in the U.S.

GSK, Pfizer and Moderna have developed RSV shots approved by the U.S. Food and Drug Administration, with GSK's Arexvy responsible for the majority of U.S. RSV vaccine sales.

(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...